Suzanne Bruhn, Ph.D. President and Chief Executive Officer |
Dr. Bruhn joined Promedior in May 2012 from Shire plc, where she was the Senior Vice President of Strategic Planning and Program Management in the Human Genetic Therapies division and she played a key role in the development of multiple protein therapeutics with annual sales today of over $1 billion. During her 13-year tenure at Shire and Transkaryotic Therapies (acquired by Shire in 2005), she was instrumental in advancing new compounds through clinical development and commercialization, with significant roles driving product strategy, portfolio management, program management, and global regulatory affairs for the rare disease portfolio. Prior to that, she was at Cytotherapeutics, Inc., with an important role developing the encapsulated cell technology platform for ophthalmic delivery. Dr. Bruhn is a member of the Board of Directors of Raptor Pharmaceuticals, a public biotechnology company, and the Crittenton Women's Union, a local non-profit organization. Dr. Bruhn was recognized as a "2013 Woman to Watch" by Mass High Tech. She was a Postdoctoral Fellow in the Department of Human Genetics at Harvard Medical School and earned a Ph.D. in Chemistry from MIT and a B.S. from Iowa State University. |
Mark L. Lupher, Jr., Ph.D. Chief Scientific Officer |
Dr. Lupher has been conducting biomedical research for nearly twenty years and has wide-ranging experience in the discovery and development of both biologic and small molecule drug candidates for the treatment of inflammatory and fibrotic diseases. He has authored numerous research articles, seminal reviews and book chapters and is the inventor on several issued and pending patent applications related to novel drug discovery. Prior to joining Promedior in 2007, Dr. Lupher held various R&D positions of increasing responsibility at biopharmaceutical companies such as Immunex and ICOS. While at ICOS, he pioneered the discovery of novel anti-fibrotic therapeutics and the development of the fibrotic disease therapeutic area. Dr. Lupher holds a B.S. degree in Microbiology from the University of Washington, a Ph.D. in Immunology from the Division of Medical Sciences at Harvard University and was a postdoctoral fellow at the Brigham and Women's Hospital. |
Elizabeth G. Trehu, M.D. Chief Medical Officer |
A veteran of the Boston biotech industry and medical community, Dr. Trehu's career has spanned the corporate biopharmaceutical, academic, and private medical practice worlds. Prior to joining Promedior, Dr. Trehu was most recently vice president of product development and medical affairs at Infinity Pharmaceuticals where, starting in 2010, she was integral in the company's rapid advancement of three clinical programs for product candidates in inflammation and oncology. Prior to Infinity, Dr. Trehu spent four years at Genzyme Corporation, where she began as vice president of oncology global medical affairs and ultimately held the position of vice president and general manager, hematology, with global responsibility for Clolar® (clofarabine), Campath® and Fludara® (fludarabine). From 2002 to 2006, she held positions of increasing responsibility in medical affairs functions at Millennium Pharmaceuticals, principally in support of Velcade® (bortezomib). Dr. Trehu's career prior to industry included laboratory and clinical research in immunotherapeutics as an assistant professor at Tufts University School of Medicine and several years in private practice as a hematologist-oncologist at the Jordan Hospital Club Cancer Center. Dr. Trehu was recognized as a '2012 Woman to Watch' by Mass High Tech. She holds an M.D. from New York University School of Medicine and an A.B. cum laude from Princeton University. |
W. Scott Willett, Ph.D. Vice President of Biopharmaceutical Development |
Dr. Willett has fourteen years of experience in the biopharmaceutical industry in development of protein purification processes for recombinant therapeutics. Prior to joining Promedior in 2007, Dr. Willett served as Director of Process Development at Neose Technologies, leading development and technology transfer for Phase I clinical manufacture of GlycoPEGylation™ processes for improved protein therapeutics. Before joining Neose, Dr. Willett was a Process Development Scientist at Amgen, where he led teams in development of Phase I cGMP purification processes for several proteins, in addition to supporting Amgen's commercial products. Dr. Willett holds a Ph.D. in Pharmaceutical Chemistry from the University of California at San Francisco, and was an NSF Post-doctoral Fellow at the University of Colorado at Boulder. He also earned a B.S. degree in Chemical Engineering from the University of Michigan at Ann Arbor. |
